29
media articles, and one longform exclusive in STAT.
The partnership and counsel that the team provided as we were launching our inaugural fund was constructive and goal oriented – I was particularly impressed by how well they listened to us. Their expertise within the life science space, especially biotech venture capital, was clear and demonstrable. The team was able to truly bring our story to life, and that was evident through the strong media coverage we received, which exceeded all of Cure’s expectations.